Six-Month Response to Delamanid Treatment in MDR TB Patients

Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing treatment for MDR TB. Results show good tolerability...

Descripción completa

Detalles Bibliográficos
Autores principales: Hewison, Cathy, Ferlazzo, Gabriella, Avaliani, Zaza, Hayrapetyan, Armen, Jonckheere, Sylvie, Khaidarkhanova, Zarema, Mohr, Erika, Sinha, Animesh, Skrahina, Alena, Vambe, Debrah, Vasilyeva, Irina, Lachenal, Nathalie, Varaine, Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2017
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621551/
https://www.ncbi.nlm.nih.gov/pubmed/28767036
http://dx.doi.org/10.3201/eid2310.170468
_version_ 1783267779299770368
author Hewison, Cathy
Ferlazzo, Gabriella
Avaliani, Zaza
Hayrapetyan, Armen
Jonckheere, Sylvie
Khaidarkhanova, Zarema
Mohr, Erika
Sinha, Animesh
Skrahina, Alena
Vambe, Debrah
Vasilyeva, Irina
Lachenal, Nathalie
Varaine, Francis
author_facet Hewison, Cathy
Ferlazzo, Gabriella
Avaliani, Zaza
Hayrapetyan, Armen
Jonckheere, Sylvie
Khaidarkhanova, Zarema
Mohr, Erika
Sinha, Animesh
Skrahina, Alena
Vambe, Debrah
Vasilyeva, Irina
Lachenal, Nathalie
Varaine, Francis
author_sort Hewison, Cathy
collection PubMed
description Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing treatment for MDR TB. Results show good tolerability and treatment response at 6 months.
format Online
Article
Text
id pubmed-5621551
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-56215512017-10-07 Six-Month Response to Delamanid Treatment in MDR TB Patients Hewison, Cathy Ferlazzo, Gabriella Avaliani, Zaza Hayrapetyan, Armen Jonckheere, Sylvie Khaidarkhanova, Zarema Mohr, Erika Sinha, Animesh Skrahina, Alena Vambe, Debrah Vasilyeva, Irina Lachenal, Nathalie Varaine, Francis Emerg Infect Dis Research Letter Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing treatment for MDR TB. Results show good tolerability and treatment response at 6 months. Centers for Disease Control and Prevention 2017-10 /pmc/articles/PMC5621551/ /pubmed/28767036 http://dx.doi.org/10.3201/eid2310.170468 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research Letter
Hewison, Cathy
Ferlazzo, Gabriella
Avaliani, Zaza
Hayrapetyan, Armen
Jonckheere, Sylvie
Khaidarkhanova, Zarema
Mohr, Erika
Sinha, Animesh
Skrahina, Alena
Vambe, Debrah
Vasilyeva, Irina
Lachenal, Nathalie
Varaine, Francis
Six-Month Response to Delamanid Treatment in MDR TB Patients
title Six-Month Response to Delamanid Treatment in MDR TB Patients
title_full Six-Month Response to Delamanid Treatment in MDR TB Patients
title_fullStr Six-Month Response to Delamanid Treatment in MDR TB Patients
title_full_unstemmed Six-Month Response to Delamanid Treatment in MDR TB Patients
title_short Six-Month Response to Delamanid Treatment in MDR TB Patients
title_sort six-month response to delamanid treatment in mdr tb patients
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621551/
https://www.ncbi.nlm.nih.gov/pubmed/28767036
http://dx.doi.org/10.3201/eid2310.170468
work_keys_str_mv AT hewisoncathy sixmonthresponsetodelamanidtreatmentinmdrtbpatients
AT ferlazzogabriella sixmonthresponsetodelamanidtreatmentinmdrtbpatients
AT avalianizaza sixmonthresponsetodelamanidtreatmentinmdrtbpatients
AT hayrapetyanarmen sixmonthresponsetodelamanidtreatmentinmdrtbpatients
AT jonckheeresylvie sixmonthresponsetodelamanidtreatmentinmdrtbpatients
AT khaidarkhanovazarema sixmonthresponsetodelamanidtreatmentinmdrtbpatients
AT mohrerika sixmonthresponsetodelamanidtreatmentinmdrtbpatients
AT sinhaanimesh sixmonthresponsetodelamanidtreatmentinmdrtbpatients
AT skrahinaalena sixmonthresponsetodelamanidtreatmentinmdrtbpatients
AT vambedebrah sixmonthresponsetodelamanidtreatmentinmdrtbpatients
AT vasilyevairina sixmonthresponsetodelamanidtreatmentinmdrtbpatients
AT lachenalnathalie sixmonthresponsetodelamanidtreatmentinmdrtbpatients
AT varainefrancis sixmonthresponsetodelamanidtreatmentinmdrtbpatients

Ejemplares similares